The recombinant protein alefacept (AmeviveĀ®) is an immunomodulator approved for the Ātreatment of moderate to severe chronic plaque psoriasis. In phase 3 clinical studies, treatment of psoriatic patients with alefacept at a safe and well-tolerated dose caused Āmeaningful reductions in psoriasis area and severity index and in physician global Āassessment scores as well…